Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.
What: Shares of Chimerix , a clinical-stage biopharmaceutical company focused on developing antiviral therapeutics, popped as much as 10% after reporting its third-quarter earnings results.
So what: For the quarter, Chimerix's revenue decreased to $0.9 million from $20.9 million in the year-ago period primarily due to one-time milestone payments received last year. The company also turned in a quarterly loss of $6.7 million, or $0.26 per share, compared to an adjusted profit of $0.11 per share last year. However, this loss was $0.13 narrower than Wall Street had expected. Chimerix also recapped its pipeline progress, which includes the initiation of a late-stage trial involving brincidofovir for the prevention of CMV in patients receiving bone marrow transplants.
Now what: Any time a clinical-stage biotech company winds up losing less money than expected, it's good news for shareholders as it means the cash burn rate is likely lessening. I would, however, suggest not getting too wrapped up in Chimerix's move higher today until we get a better idea of how its brincidofovir late-stage data looks. I often get criticized for missing the big moves in biotech stocks for taking the conservative approach, but I also tend to avoid those calamitous 50%+ down days by playing it safe. I would certainly suggest the conservative approach may be your best bet with Chimerix.
You don't have to wait with this growth stock
Although Chimerix may offer a lot of promise, you don't have to wait to check out this incredible tech stock -- which is growing twice as fast as Google and Facebook, and more than three times as fast as Amazon.com and Apple. Watch our jaw-dropping investor alert video today to find out why The Motley Fool's chief technology officer is putting $117,238 of his own money on the table, and why he's so confident this company will be a huge winner in 2013 and beyond. Just click here to watch!
The article Why Chimerix Inc. Shares Jumped originally appeared on Fool.com.Fool contributor Sean Williams has no material interest in any companies mentioned in this article. You can follow him on CAPS under the screen name TMFUltraLong, track every pick he makes under the screen name TrackUltraLong, and check him out on Twitter, where he goes by the handle @TMFUltraLong . Try any of our Foolish newsletter services free for 30 days . We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy .
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.